A painful but common condition in older adults is shingles or herpes zoster. I’ve known several elderly people afflicted with this, and I will absolutely get the vaccine as soon as I turn 60!
The vaccine, Zostavax, is FDA-approved for ages 50 and up, but the Cleveland Clinic recently advised that it’s not cost effective for anyone under 60 to get immunized.
Why? Because Zostavax is too expensive. On average, it costs about $200, and that doesn’t include the cost for the office visit or vaccine administration that some clinics charge.
The vaccine is effective for 10-12 years, so … Continue reading
A year ago I posted about the worrying trend of generic medications—a mainstay of affordable health care—rising in price by 100%, 200%, 1000% or more. My husband’s levothyroxine, for example, has increased in price by over 600% since 2013.
The common and used-to-be-dirt-cheap antibiotic, doxycycline, has gone up a whopping 6,000%!
Unfortunately, this trend has not stopped.
The latest old-drug, new-price story is that of Daraprim (pyrimethamine). Last month Turing Pharmaceuticals bought this drug and immediately jacked up the price from $13.50 per tablet to $750, an increase of over 5,000%.
The New York Times, I think, had the … Continue reading
I participate in a world-wide group of health care providers that exchanges information about the high costs of health care and overtreatment in our respective countries. (It’s not just an American problem!)
One provider recently shared for our consideration a paper that stated too many third molars (aka wisdom teeth) were being unnecessarily removed in the US.
Ten million third molars (wisdom teeth) are extracted from approximately 5 million people in the United States each year at an annual cost of over $3 billion.
In addition, more than 11 million patient days of “standard discomfort or disability”—pain, swelling, bruising, and
… Continue reading
Earlier this summer the Food and Drug Administration (FDA) approved the first of a new type of cholesterol-lowering medication, the PCSK9 inhibitors.
The drug companies Sanofi and Regeneron got that honor with their drug Praluent (alirocumab). But not too far behind will be Amgen with Repatha (evolocumab) and Pfizer with borocizumab. (Who names these drugs, anyway?)
Although Praluent is not yet available in pharmacies, its announced price tag has the medical community (and insurers) in an uproar. Pharmaceutical executives are doing their best to rationalize the expense—spend a lot of money up front and maybe save more money down … Continue reading
It’s almost that time of year when insurance companies start sending out information about next year’s plans and what may or may not have changed in their policies, such as premiums and benefits.
A little-known new rule of the Affordable Care Act (ACA) will take effect on January 1, 2016, and might affect your health insurance plan and health care costs.
Specifically, this rule takes away what’s been called the “umbrella limit” on out-of-pocket maximums for families.
If you currently have a family policy with a family out-of-pocket maximum (up to $13,200 in 2015), even if only one family … Continue reading
I’ve posted before about how expensive it is to be treated for cancer.
Recently, a patient posted on the health blog KevinMD about her experience dealing with not only the stress of metastatic ovarian cancer, but the struggle to stay afloat financially.
I am one of many people today “living” with cancer. I want to focus on the impact cancer has on my personal finances, and this is probably true for any chronic illness, not just cancer.
Never in my wildest dreams did I think I’d be diagnosed with stage 4 ovarian cancer at 51 years old. I really
… Continue reading
Two big health insurance mergers are in the works: Aetna plans to buy Humana for $33 billion, and Anthem will take over Cigna for a whopping $54.2 billion.
The number of major health insurers in the US will soon be three, down from five.
So much for more competition, huh?
What’s happening in the health care delivery system mirrors the insurance industry. The biggest health care corporations are furiously buying up smaller hospitals and physicians’ groups.
From their points of view, it makes sense: Each side believes being bigger will give them the upper hand in reimbursement negotiations (that is, … Continue reading
“Cover-your-ass health care” or “save-my-ass medicine” are terms used to describe all the extra diagnostic tests (blood tests, CT scans, MRIs, etc.) ordered by physicians to rule out possible (but unlikely) life-threatening conditions.
Such as going to the emergency department with a headache and getting a CT scan to rule out an aneurysm or a brain tumor.
Or, as in this video example, being worked up for a heart attack when the most likely diagnosis is a simple case of heartburn. (Warning: video contains some bad language!)
The ER physician in the video is certainly … Continue reading
Two recent stories from Kaiser Health News caught my attention because they underscore the burden placed on patients to understand exactly what services their health insurance does or doesn’t cover.
Of course everyone should know their health plan’s benefits, but with so many different types of plans, and the hair-pulling-out frustrations of narrow networks, it can be really difficult. Unfortunately, the financial consequences of making a mistake are heavier than ever.
The first story tells of a … Continue reading
One of the premises of Obamacare was that if patients were expected to pay more towards their health care—have more “skin in the game”—they would shop around for the best prices and spend less.
I posted about how difficult, if not impossible, it is for patients to shop for health care. Prices are not as transparent as some policy makers would like to think.
Related post: Researching health care costs
A recent article in Kaiser Health News confirms this:
Douglas White knew high-deductible insurance is supposed to make patients feel the pain of medical prices and turn them
… Continue reading
Here we go again!
Every May, health insurance companies file their requests for premium increases for next year’s plans.
I’ve been watching my state’s website for the Office of the Insurance Commissioner. Rate increases for all health plans—group, small business, and individual (both on and off the health exchange)—are posted for public review and comment.
The insurance commissioner has until late summer to either approve, disapprove or modify the increase. Insurance companies are required to give their subscribers a 90-day notice of any premium increases.
My insurance company is asking for a 9.6% rate hike. Our family’s premium will go … Continue reading
A friend of mine who is an avid reader of both The New Yorker and my blog sent me the following link: Overkill: An avalanche of unnecessary medical care is harming patients physically and financially. What can we do about it?
The author is Atul Gawande, MD, one of my favorite surgeon/writers. It’s a long article, but if you are interested in saving money on your health care (and possibly saving your health), I encourage you to take time to read it.
I have posted many times about America’s obsession with overtreatment—too many tests, too many specialists, too many … Continue reading
I just received an email from my insurance company, Premera Blue Cross.
Dear subscriber, talk to a real doctor anytime, anywhere!
Set up your account with Teladoc.
And get medical care anytime, anywhere for $40 or less.
You and your eligible dependents can now get care from U.S. board-certified doctors and pediatricians by phone or online video with Teladoc®.
A real doctor? I’m not sure why they felt it necessary to add that adjective.
But aside from that, I was intrigued by the idea that my insurance company wanted to support, even encourage, my family’s use of telemedicine, so I … Continue reading
A report published last week detailed how much Medicare spends on prescription medications.
In 2013, Medicare spent $103 billion on drugs. (I’m guessing the total will be more in 2014 and 2015, when they get around to publishing that data.)
Federal officials said they hoped that disseminating the data would lead to new revelations about the prescribing patterns of doctors and for particular drugs.
Dan Mendelson, the CEO of Avalere, a Washington, D.C., consulting firm, said the data could provide patients with new questions about their prescription history when they visit their physician. “It’s really important to stimulate conversations
… Continue reading
It’s another case in which the right hand of a behemoth government agency doesn’t know what the left hand is doing: In Cancer Wars, It’s Doctors vs. Hospitals
Colliding federal policies are fomenting a nasty money war that’s pitting community oncologists trying to treat patients in less expensive clinic settings against hospitals trying to woo patients in through costlier emergency departments.
The agencies under discussion are the Centers for Medicare and Medicaid Services (CMS) and the Health Resources Services Administration (HRSA) [which both fall under the larger umbrella of the Department of Health and Human Services (HHS)], and their disparate … Continue reading